Concomitant renal insufficiency and diabetes mellitus as prognostic factors for acute myocardial infarction

Study design and patient population

The study population was enrolled in a nationwide prospective Korea Acute Myocardial Infarction Registry (KAMIR) from November 2005 to August 2008. This study was a retrospective cohort of 9905 consecutive patients (mean age ± standard deviation [SD], 63 ± 13 years; 70% men) whose discharge diagnosis was AMI based on clinical symptoms, cardiac enzyme levels, and 12-lead electrocardiogram [14]. This study included patients who were available to calculated estimated GFR. The patients with underlying malignancy were excluded. All of the patients completed at least 1 year of follow-up.

The KAMIR, launched in November 2005, is a Korean prospective multicenter data collection registry reflecting real-world treatment practices and outcomes in Asian patients diagnosed with AMI. The registry consists of 52 community and university hospitals with facilities for primary percutaneous coronary intervention (PCI), thrombolytic therapy and on-site cardiac surgery. Data were collected by a well-trained study coordinator based on a standardized case report form and protocol. The study protocol was approved by the ethics committee at each participating institution and all patients were informed about their participation in this registry.

For simplicity of analysis and presentation, all patients were categorized into 4 groups according to the presence of diabetes mellitus and renal insufficiency (glomerular filtration rate [GFR] < 60 ml/min/1.73 m²). Group I (n = 5700) had neither diabetes mellitus nor renal insufficiency (GFR ≥ 60 ml/min/1.73 m²); Group II (n = 1730) had diabetes mellitus but no renal insufficiency; Group III (n = 1431) had no diabetes mellitus but renal insufficiency; Group IV (n = 1044) had both diabetes mellitus and renal insufficiency.

Definition

Diabetes mellitus was defined as fasting plasma glucose level of 126 mg/dl or greater on at least 2 occasions, plasma glucose of 200 mg/dl or greater at 2 h after a 75-g oral glucose tolerance test, the need for insulin or glucose-lowering medication to control glucose levels on admission, or medical history of diet-controlled diabetes. Among AMI patients, ST-segment elevation acute myocardial infarction (STEMI) was defined as new ST-segment elevation of > 2 mm in ≥ 2 pre-cordial leads or > 1 mm in ≥ 2 limb leads, or a new onset of left bundle branch block on the 12-lead electrocardiogram with a concomitant increase of at least one cardiac biomarker of necrosis (e.g., creatine kinase-MB, troponin I, or troponin T). Non-ST-segment elevation acute myocardial infarction (NSTEMI) was defined as the exception of STEMI. Left ventricular ejection fraction (LVEF) was checked by two-dimensional echocardiography.

Assessment of renal function

Renal insufficiency was defined as an estimated GFR of < 60 ml/min/1.73 m² calculated using the Modification of Diet in Renal Disease (MDRD) [15] formula, including age, ethnicity, sex, and serum creatinine: GFR, in ml/min per 1.72 m² = 1.86 × (serum creatinine [ml/min])^-1.154 × (age)^-0.203 × (0.742 [for women]). Serum creatinine was analyzed by the alkaline picrate method performed using an Olympus 5431^® device (Olympus Optical Co. Ltd., Tokyo, Japan). The level of creatinine was measured prior to angiography, and renal function was assessed based on the estimation of GFR.

Study endpoint

The primary endpoints were major adverse cardiac events (MACE), including a composite of all cause-of-death, myocardial infarction, target lesion revascularization, and coronary artery bypass graft during the 12-month clinical follow-up. Target lesion revascularization was defined as any revascularization of the target lesion because of restenosis or reocclusion within the stent or adjacent 5-mm border.

Statistical analysis

Continuous variables are presented as means ± SD, and categorical variables as number of cases and percentages. Comparative analysis was performed within the groups or as a whole using either analysis of variance (ANOVA) or Student's t-test for continuous variables, and Pearson chi-square test or Fisher's exact test for categorical variables. Continuous variables with skewed distribution were presented as median (with 25th and 75th percentiles) and compared by using the Kruskal-Wallis test. Logistic regression was performed to identify the independent predictors of MACE at 1-year clinical follow-up. Multivariate Cox regression analysis was adjusted by previous medical knowledge and independently of p value: age, sex, body mass index, systolic blood pressure on admission, heart rate, Killip class > I, history of hypertension, dyslipidemia, coronary artery disease, smoking, multivessel disease, LVEF < 55%, medication of statin, low-density lipoprotein cholesterol, and N-terminal pro-brain natriuretic peptide (NT-pro BNP) of > 3000 pg/ml. The probability of death was estimated by the Kaplan-Meier method, and curves were compared with the log-rank test. All statistical tests were 2-tailed, and p < 0.05 was considered significant. Analyses were performed using the Statistical Package for Social Sciences software, version 17.0 (SPSS, Chicago, Illinois).

Baseline characteristics of the study patients

Angiographic and procedural characteristics

In-hospital mortality and clinical outcomes during follow-up

Clinical outcomes in hospital and at 1 month and 12 months after discharge are listed in Table 3. Group IV had a significantly higher incidence of composite MACE, myocardial infarction, and death after 1-month and 12-month clinical follow-up. There was a stepwise increase in 12-month composite MACE in patients of Group I through IV (Figure 1). However, target lesion revascularization at 1 month and coronary artery bypass graft at 12 months were not significantly different among the groups. In patients with no renal insufficiency (Groups I and II), those with diabetes had significantly more 12-month composite MACE than those without diabetes (12.5% versus 15.7%, respectively; p = 0.001). In patients with renal insufficiency (Groups III and IV), the same was observed (30.5% versus 36.5%, respectively; p = 0.002). However, there were no significant differences between diabetic and non-diabetic patients with regard to 12-month mortality in the renal insufficiency groups (25.3% in Group III versus 27.5% in Group IV; p = 0.212). Thus, both myocardial infarction and target lesion revascularization might be affecting the increase of 12-month composite MACE in diabetic patients with renal insufficiency. Kaplan-Meier curve analysis (Figure 2) revealed that patients with diabetes had significantly higher death rates than those without diabetes under no renal insufficiency conditions (p = 0.006). The same was not observed in diabetic and non-diabetic patients with renal insufficiency (p = 0.288).

	Group I (n = 5702)	Group II (n = 1731)	Group III (n = 1432)	Group IV (n = 1044)	p Value
					Overall	Linear†
In-hospital outcomes (n = 9905)
In-hospital death (%)	168(3)	66(4)	249(18)	185(18)‡	< 0.001	< 0.001
1-month outcomes
Composite MACE (%)	327 (5.7)	128(7.4)¶	317(22.2)	257(24.6)‡	< 0.001	< 0.001
Death (%)	225(3.9)	84(4.9)	296(20.7)	226(21.6)‡	< 0.001	< 0.001
MI (%)	28(0.5)	12(0.7)	4(0.3)	19(1.8)‡	< 0.001	0.001
Re-PCI (%)	57(1.0)	21(1.2)	16(1.1)	7(0.7)	0.559	0.649
CABG (%)	17(0.3)	11(0.6)	1(0.1)	5(0.5)	0.039	0.807
12-month outcomes
Composite MACE (%)	715 (12.5)	271 (15.7)¶	436 (30.5)	381 (36.5)‡§	< 0.001	< 0.001
Death (%)	287(5.0)	117 (6.8)¶	361 (25.3)	287 (27.5)‡	< 0.001	< 0.001
MI (%)	44(0.8)	20 (1.2)	10 (0.7)	25 (2.4)‡§	< 0.001	< 0.001
Re-PCI (%)	385(6.3)	120 (6.9)	59 (4.1)	62 (5.9)§	0.006	0.082
CABG (%)	26 (0.5)	14 (0.8)	6 (0.4)	7 (0.7)	0.280	0.455

Groups are as in Table 1.

Abbreviations: MACE, major adverse cardiac event; MI, myocardial infarction; Re-PCI, target lesion revascularization; CABG, coronary artery bypass graft.

†Statistical significance for linear-by-linear association between categorical variables calculated using chi-square-test for trend.

¶ p < 0.05 Compared with Group I.

‡p < 0.05 Compared with Group II.

§ p < 0.05 Compared with Group III.

Cox regression analysis for mortality during follow-up

Independent predictors of major adverse cardiac events

Correlation between clinical outcomes and presence of renal insufficiency and diabetes in patients with AMI

Our findings confirm those of previous studies [1, 2, 6, 16] that deteriorating renal function predicts mortality after AMI. In our study, renal insufficiency groups (Group III and IV) had higher composite MACE occurrence and mortality after a 12-month follow-up as compared with groups with no renal insufficiency. There are several potential links between renal insufficiency and increased number of cardiovascular events. First of all, renal insufficiency is accompanied by anemia, high level of homocysteine, increased oxidation of low-density lipoproteins, and diminished nitric oxide production, which may result in accelerated atherosclerosis, endothelial dysfunction, and poor outcome after myocardial infarction [21–23]. In addition, left ventricular hypertrophy accompanying advanced renal failure is an important risk factor for mortality resulting from cardiovascular disease. In the clinical setting, renal insufficiency might be another useful surrogate marker for cardiovascular disease in the patients with diabetes, because the estimated GFR was associated with both the intima-media thickness and the brachial-ankle pulse wave velocities in previous study [24]. Moreover, diabetic patients with non-albuminuric renal impairment had higher prevalence of cardiovascular disease than those with albuminuria and non-reduced estimated GFR [25–27]. Therefore, renal impairment is a powerful predictor of cardiovascular disease morbidity and mortality in diabetic patients. Similarly, in our study, angiographic findings such as left main coronary artery disease and ACC/AHA lesion scores were more severe in renal insufficiency than in non-renal insufficiency groups.

Diabetic patients with AMI hold poorer clinical outcomes than non-diabetic patients [19]. Our findings supported the observation that patients with diabetes have more composite MACE at 1 year of follow-up than those without diabetes, regardless of renal insufficiency. Multiple mechanisms have been implicated in the increased number of adverse outcomes in diabetes patients. These mechanisms include an abnormal metabolic response to ischemia with inefficient energy use and accumulation of deleterious oxygen-free radicals [28], greater endothelial dysfunction [29], and abnormalities of thrombosis and fibrinolysis [30]. Recently, Yan et al. [31] demonstrated a significant association between plasma osteopontin levels and the presence and severity of coronary artery disease in diabetic patients, indicating that osteopontin may be critically involved in the inflammatory processes resulting in accelerated atherosclerosis. Patients with diabetes are known to have a greater atherosclerosis burden, with more diffuse and more multivessel coronary artery disease, as seen in our study.

Taking all our findings together, we suggest that concomitant occurrence of renal insufficiency and diabetes in patients with AMI represent not only severity of disease or clinical outcome, but also serve as prognostic predictor of cardiovascular risk, including composite MACE and all-cause mortality.

Clinical relevance of the classification according to renal insufficiency and diabetes in patients with AMI

The present study demonstrated that simply categorizing patients into 4 groups according to the presence and absence of diabetes and renal insufficiency was efficient in differentially predicting 1-year clinical outcome after AMI. Despite no significant differences between Group I and Group II in multivariate Cox regression analysis, we found a stepwise increase in the HR for 12-month mortality from Group I through Group IV. These observations were further supported by the fact that patients in higher groups were older, had a higher prevalence of hypertension and previous coronary artery disease, and lower LVEF compared with Group I, all of which may induce atherosclerosis and contribute to increased cardiovascular mortality. In this respect, we also found that several molecular markers, including NT-pro BNP and hs-CRP were increased from Group I through IV. Such markers are affected not only by the degree of heart failure, but also by inflammation [32, 33], which might have increased the risk of cardiovascular mortality in our patients with AMI. Therefore, this study suggests that categorization of patients according to the presence of diabetes and renal insufficiency provides valuable information for early-risk stratification of patients with AMI.

Recently, a single-center prospective study [13] encompassing 3334 AMI patients divided into those without diabetes, with diabetes and chronic kidney disease (CKD), and with diabetes and without CKD, suggested that mortality and MACE rates did not differ significantly between diabetes patients without CKD and patients without diabetes. Diabetes coexisting with CKD, however, was found to be one of the strongest independent risk factors for cardiovascular complications and total mortality, in agreement with our findings. On the other hand, some differences in the clinical outcomes were observed in our study. The non-diabetic patients were divided into 2 groups according to presence or absence of renal insufficiency, and non-diabetic patients with renal insufficiency (Group III) had higher mortality and 12-month composite MACE than diabetic patients without renal insufficiency (Group II). On the contrary, patients without diabetes and renal insufficiency (Group I) had less severe adverse clinical outcomes following AMI than diabetic patients without renal insufficiency (Group II).

Anavekar et al. [12] showed that patients with or without diabetes present a similar relationship between renal insufficiency and cardiovascular risk, including all-cause mortality, death, a composite of heart failure, recurrent AMI, resuscitated sudden cardiac death, and stroke, after high-risk AMI. In agreement with a previous study [12], our study demonstrated that the mortality at 12 months of follow-up was not different between diabetic and non-diabetic patients with renal insufficiency after AMI. This indicates that patients with renal dysfunction might be more susceptible to severe and diffuse coronary artery disease, regardless of diabetes. Indeed, such patients present a high prevalence of left ventricular hypertrophy and hypertension, both of which are markers of increased cardiovascular risk [34, 35].

Although patients with and without diabetes experience increased cardiovascular event rates with worsening of renal function, patients with diabetes consistently show higher proportions of events than non-diabetic patients according to decreasing renal function [12]. Consequently, diabetes and renal insufficiency independently or synergistically are related with an increase in cardiovascular events after AMI. Therefore, we underline the importance of classifying patients into 4 large groups according to presence or absence of diabetes and renal insufficiency for predicting mortality and cardiovascular complications in patients following AMI.

Study limitations

Nonetheless, the present study has several limitations. The best validated method to calculate estimated GFR is the MDRD formula. However, this formula has not been specifically validated in patients with diabetes [36]. With respect to increasing GFR in patients with early diabetes, the influence of GFR changes was not addressed. In addition, even healthy but more than 65 years old female subjects can reach a GFR of less than 60 ml/min/1.73 m², indicating that the definition of renal insufficiency is weak. Secondly, since our study was retrospective and non-randomized, it may reflect selection bias. Third, although most confounders were included in the multivariate analysis, it is possible that some confounders were excluded. Finally, clinical data encompassed a 1-year period in our study. Thus, long-term clinical outcomes could not be fully evaluated. Large-scale long-term prospective randomized trials are needed in the future.